Amgen (AMGN) Stock Forecast: What Could Drive It in 2026
Short answer
No one can reliably forecast AMGN's price, and Walnut does not publish targets. What is useful is the setup. For Amgen, the drivers that could push it higher are real, and so are the risks that could weigh on it. Below is each side plus a framework to form your own view. This is descriptive, not a prediction or a recommendation.
What could drive Amgen (AMGN) higher?
1. Rare disease and Horizon assets.
The Horizon Therapeutics acquisition added higher-growth rare-disease drugs such as Tepezza and Krystexxa, diversifying Amgen away from older, slower-growing franchises and giving it newer products with patent runway and pricing power in specialty markets.
2. Obesity and metabolic pipeline.
Amgen is developing candidates in the obesity and metabolic space, including investigational GLP-1-class and related therapies. Success in this large and fast-growing market could provide a significant new growth driver, though the candidates must still clear late-stage trials and regulatory review.
3. Biosimilars and cash generation.
As blockbuster biologics lose exclusivity industrywide, Amgen is both defending its own products and selling biosimilars of competitors' drugs. Combined with strong free cash flow, this supports a growing dividend and buybacks, giving the stock an income and capital-return component on top of pipeline optionality.
What could weigh on AMGN?
Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions.
How to think about a AMGN forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the AMGN guide and whether AMGN is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the AMGN outlook
The honest bottom line: Amgen (AMGN)'s outlook hinges on whether its drivers (above) outpace its risks, and no one can promise which wins. Treat any AMGN forecast as a scenario, not a certainty, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around AMGN with Walnut
Use Amgen as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Amgen (AMGN)?
+
No one can reliably predict where AMGN will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Amgen higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive AMGN higher?
+
The main growth drivers are Rare disease and Horizon assets; Obesity and metabolic pipeline; Biosimilars and cash generation. Whether they play out is the real question, not a guaranteed path.
What are the risks to AMGN?
+
Amgen faces patent cliffs as older blockbusters lose exclusivity, exposing them to biosimilar competition and pricing pressure. Drug development is high-risk: pipeline candidates, including its obesity programs, can fail in late-stage trials or face regulatory setbacks. US drug-pricing policy, including Medicare negotiation under the Inflation Reduction Act, pressures margins on key products. The Horizon acquisition added debt. Litigation, manufacturing, and safety risks are inherent to the industry. Verify the latest pipeline and revenue trends before drawing conclusions.
Will AMGN stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Amgen's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is AMGN a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the AMGN "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.